A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Study Identifier:
CLI-06657AA1-10
ClinicalTrials.gov Identifier:
NCT06663358
EudraCT Identifier:
N/A
Study Contact Information:
(888) 661-9260 or [email protected]
Recruiting

Study Details

Medical Condition
  • Fabry Disease
Study Drug
  • Drug: Pegunigalsidase-alfa
Date
Nov 2024 - Nov 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Healthy Volunteers
No

Protocol Summary

A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.

Study Locations

Location
Status
Location
Infusion Associates
Grand Rapids, Michigan, United States, 49525
Status
Recruiting